DDAVP TABLETS 0.1MG
Land: Canada
Språk: engelsk
Kilde: Health Canada
Preparatomtale
(SPC)
31-12-2015
Noen dokumenter for dette produktet er ikke tilgjengelig for øyeblikket, du kan sende en forespørsel til kundeservicen vår, og vi vil varsle deg så snart vi kan få dem.
Send forespørsel.
Send forespørsel.
Aktiv ingrediens:
DESMOPRESSIN ACETATE
Tilgjengelig fra:
FERRING INC
ATC-kode:
H01BA02
INN (International Name):
DESMOPRESSIN
Dosering :
0.1MG
Legemiddelform:
TABLET
Sammensetning:
DESMOPRESSIN ACETATE 0.1MG
Administreringsrute:
ORAL
Enheter i pakken:
30
Resept typen:
Prescription
Terapeutisk område:
PITUITARY
Produkt oppsummering:
Active ingredient group (AIG) number: 0112050005; AHFS:
Autorisasjon status:
CANCELLED POST MARKET
Autorisasjon dato:
2022-05-31
Preparatomtale
_DDAVP Tablets 0.1 mg and 0.2 mg _
_Template Date: January 2010 _
_Page 1 of 29 _
PRODUCT MONOGRAPH
PR
DDAVP
® TABLETS
Desmopressin Acetate
0.1 mg and 0.2 mg Tablets
Antidiuretic
Ferring Inc.
200 Yorkland Boulevard
Suite 500
North York, Ontario
M2J 5C1
Date of Revision:
DECEMBER 17, 2015.
CONTROL NUMBER: 187744
_DDAVP Tablets 0.1 mg and 0.2 mg _
_Template Date: January 2010 _
_Page 2 of 29 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
...........................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
....................................................................................................6
DRUG INTERACTIONS
....................................................................................................7
DOSAGE AND ADMINISTRATION
................................................................................8
OVERDOSAGE
................................................................................................................10
ACTION AND CLINICAL PHARMACOLOGY
............................................................10
STORAGE AND STABILITY
..........................................................................................13
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................13
PART II: SCIENTIFIC INFORMATION
...............................................................................14
PHARMACEUTICAL INFORMATION
..........................................................................14
CLINICAL TRIALS
............................................................................................
Les hele dokumentet
